March 30, 2017 | Blake Mossy
Organogenesis entered into an agreement to acquire NuTech Medical, a developer of amniotic biologic products for the wound healing and surgical orthopedic markets.
NuTech, founded in 1994, and headquartered in Birmingham, AL, offers a line of products that utilize amniotic tissues and fluids which address both soft tissue and bone applications. The company’s platform technology aims to promote regenerative, anti-inflammatory, anti-scarring, and angiogenic properties once in contact with the patients’ anatomy. Within the orthopedics market, NuTech provides anterior cervical plate systems, allograft interbody spacers, and thoracolumbar pedicle screw systems. The company also has a non-biologics platform, which Organogenesis will not be acquiring in this transaction and will remain as a separate entity, NuSpine.
Under the terms of the agreement, NuTech Medical will operate at its current facilities as a division of Organogenesis, however, management anticipates to expand the existing surgical sales network through hiring additional representatives. NuTech’s President and CEO, Howard Walthall, will join Organogenesis as President of the Surgical Division, and Senior Vice President of Strategy and Development.
The transaction combines two companies with highly complementary regenerative wound care and surgical biologic product portfolios. Additionally, this acquisition allows Organogenesis to enter the amniotic segment of the biologics space.